`
`Inventors: OKSCHE el al.
`
`Confirmation No.: T0 be assigned
`
`Applicant: Rhodes Pharmaceuticals LP.
`
`Art Unit: T0 be assigned
`
`Appl. No.: T0 be assigned
`
`Examiner: T0 be assigned
`
`(Divisional oprpl. No. 15/135, 794;
`
`Atty. Docket: 1861.2700006/J1VIC/1VISB
`
`Filed: April 22, 2016)
`
`Filing Date: Herewith
`
`Title: BUPRENORPHINE WAFER FOR DRUG SUBSTITUTION THERAPY
`
`Authorization to Treat a Reply as Incorporating an
`Extension of Time Under 37 C.F.R. § 1.136(a)(3)
`
`Commissioner for Patents
`
`PO Box 1450
`
`Alexandria, VA 22313-1450
`
`Sir:
`
`The US. Patent and Trademark Office is hereby authorized to treat any reply that requires a
`
`petition for an extension of time for its timely submission, as incorporating a petition for extension
`
`of time for the appropriate length of time. The US. Patent and Trademark Office is hereby
`
`authorized to charge all required extension of time fees to our Deposit Account No. 19-003 6, if such
`
`fees are not otherwise provided for in such reply.
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & Fox P.L.L.C.
`
`/Matthew S. Bodenstein/
`
`Matthew S. Bodenstein
`
`Attorney for Applicants
`Registration No. 58,885
`
`Date:
`
`September 19, 2017
`
`l 100 New York Avenue, NW.
`Washington, DC. 20005-3934
`(202) 371-2600
`821939371D0C
`
`